February 22nd 2024
Differences between IEC and non-IEC post-relapse outcomes showed some significance in PFS but not in ORR.
February 20th 2024
Integrating the Latest Algorithms for Prophylaxis and Treatment of Acute and Chronic GvHD: How the Experts Think and Treat
February 23, 2024
Maximizing Our Clinical Practices in Hodgkin Lymphoma: Integration of Recent Data Sets in Real World Settings
ACCC 50th Annual Meetings & Cancer Center Business Summit Pre-Conference: Clinical Updates from San Diego in Hematologic Malignancies
February 28, 2024
Community Practice Connections™: Matching the Tumor With Patient-Specific Goals to Inform Frontline Selection and Sequencing in Chronic Lymphocytic Leukemia
State-of-the-Art CMV Care: Experts’ Perspectives on Primary/Secondary Prevention and Management of Refractory/Resistant Infections
MRD Assessment as a Cornerstone to Clinical Decision-Making in Hematologic Malignancies: Techniques, Utilization, and Best Practices to Optimize Patient Outcomes
Cancer Summaries and Commentaries™: Report from New Orleans on the Latest Updates in GvHD Prevention and Treatment
28th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma
February 29, 2024 - March 3, 2024
The assistant professor of neurology at University of Washington, Seattle Children's discussed efforts to address a gap in knowledge in the long-term effects of CAR-T, if any, on children’s neurological development.
Funding from ACGT will help Chiocca perform FDA-required studies on mice to show the oncolytic virus is safe and can be manufactured for humans. It is the second such grant awarded to Chiocca from ACGT.
Peter A. Merkel, MD, MPH, the chief of the Division of Rheumatology and a professor of medicine and professor of epidemiology at Penn Medicine, discussed clinical trial design considerations for this emerging field.
The executive director of global clinical development at Ultragenyx Pharmaceutical discussed the statistical findings she presented at the 2024 WORLDSymposium.
Iovance’s tumor infiltrating lymphocyte (TIL) therapy is the first cellular therapy to earn this indication, with the phase 3, confirmatory TILVANCE-301 trial set to verify its clinical benefit.
David Porter, MD, the director of cell therapy and transplant at Penn Medicine, discussed the importance of sharing knowledge in the emerging field of cell therapy for autoimmune disease.
The chief of the Division of Rheumatology and professor of medicine and professor of epidemiology at Penn Medicine discussed challenges on the horizon in this rapidly emerging field.
The clinical research director of the UCSF Multiple Sclerosis Center discussed the importance of rigorous clinical trial design for determining whether CAR-T will truly be of benefit in autoimmune disease.